Yeah maybe I should shirt the stock like you did, good idea, could have made big bucks lol
I quite agree with your assessment of clinical stage bio companies as expensive experiments.
Out of curiosity I checked the reverse stock split history for Sangamo and came up with zero, which I found interesting.
Ever since Amgen went public in 1984 investors have placed high hopes on the possibility of hitting the Big One.
The biotech, biomed, medical device sector is actually the largest sector in terms of available public traded companies in which one
can invest. More go public every week.
The stock has certainly experienced some dramatic ups and downs since 2000
Most bios are expensive experiments done by expensive PhDs. They are Wall St. shows nobody should stick around for the endings.
Over 28 years with no success, allowing others to overtake them, while they created an unsustainable infrastructure. They couldn't even license their AAV capsids or ZFP-TFs, instead having to settle for a nominal "evaluation agreements" with Prevail and Chroma.
Worse still, have around a year of cash on hand unless they decide to address their costs. Does anyone know when the company plans on breaking even? Will it be in '26 or '27 if their haemophilia therapy is approved in '25? Also, they will need to rise, and with the current price it's going to be (extremely) dilutive. If the therapy isn't approved, I don't see how the company isn't toast.
It was uplifting and important to close at a dollar yesterday.
I'm not ready to put a fork in it yet. I think there's still a considerable pulse.
The company is essentially dead.
Are you familiar with EDIT? How well they are they doing after winning a patent fight with CRSP?
Looks like it's doing exactly what I predicted. I'll be adding more if it dips below $15.
loved how everyone was hatting this company at $9.00 2 month later its 20 so much cash and partnerships 30.00 target next year loaded up for more upside on SGMO & HGEN favorite two gene editing stocks both in phase 3
Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells
Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization
No, I think it plays catchup to the sector. $EDIT $CRSP $NTLA are too hot...
I think later next year if we see positive results coming in from the studies the stock will move much higher. In the meantime we could be range bound between 14-20. I'm not so sure we're a take over candidate with all the collaborations we have. It's really a poison pill. It sure would be a very complex buyout.
SGMO Sangamo has prioritized intellectual property as an essential component of their business. They have a dominant proprietary patent estate for zinc fingers design and methods. They also own more CRISPR patents than CRISRP (CRSP), Editas (EDIT) and Intellia (NTLA) combined. The 2019 CRISPR 10k states they own approximately 25 granted patents worldwide, relying primarily on in-licensing which is clouded by ongoing patent litigation. https://seekingalpha.com/article/4395956-sangamo-good-companies-get-bought-not-sold
Got some Jan $20 calls
A double from here looks very doable comparing market caps to $CRSP $EDIT $NTLA
SGMO moving toward stratosphere, finally...50-100.
What happened to the hiv drug they had years ago.
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.